Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | PDE5A | O76074 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | RORC | P51449 | 8/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.34 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.34 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1551027 | 0.86 | NR1H2 (0.47) | MAPTPDE5AGRM2NR1H2NR1H3 | |
| SCHEMBL1551636 | 0.79 | NR1H2 (0.47) | PDE5AGRM2NR1H2NR1H3RORC | |
| SCHEMBL1551471 | 0.79 | NR1H2 (0.47) | MAPTPDE5ANR1H2NR1H3RORC | |
| SCHEMBL1551575 | 0.78 | RORC (0.39) | MAPTGRM2NR1H2NR1H3RORC | |
| SCHEMBL1552322 | 0.78 | NR1H2 (0.53) | GRM2NR1H2NR1H3RORCAKR1B1 | |
| SCHEMBL1976127 | 0.74 | NR1H2 (0.42) | NR1H2NR1H3RORCAKR1B1 | |
| SCHEMBL1552095 | 0.73 | NR1H2 (0.48) | NR1H2NR1H3RORC | |
| SCHEMBL1551611 | 0.73 | KCNK3 (0.41) | MAPTNR1H2NR1H3RORC | |
| SCHEMBL1551105 | 0.73 | NR1H2 (0.52) | GRM2NR1H2NR1H3RORC | |
| SCHEMBL599275 | 0.72 | HSD11B1 (0.39) | MAPTPDE5AGRM2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2313376-B1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-24 | — | — | EP | claimed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | claimed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | claimed |
| EP-2313376-B1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI SA (FR) | 2014-12-24 | — | — | EP | disclosed |
| US-8410099-B2 | Substituted 1-benzyl-cinnolin-4(1H)-one derivatives, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2013-04-02 | — | — | US | disclosed |
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-06-16 | — | — | US | disclosed |
| EP-2313376-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010004215-A2 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144115-A1 | SUBSTITUTED 1-BENZYL-CINNOLIN-4(1H)-ONE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | CNR1, CNR2, GPR18 | MAPT 3118/4885PDE5A 3635/4885GRM2 738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.